Bristol Myers Squibb Celebrates New Expansion in Brisbane
On Thursday, September 21st, 2023, Bristol Myers Squibb leadership, colleagues and local community leaders came together to celebrate the evolution of their Brisbane Research and Development (R&D) site bringing together world class scientific teams that span research and clinical development in cardiovascular disease, hematology, oncology and immunology to advance new therapeutics for people with serious diseases.
A ribbon cutting ceremony marked the addition of 27,000-square feet of lab and office space at 1200 Sierra Point Parkway to their growing footprint in Brisbane and San Mateo County. With panoramic views of the San Francisco Bay, the new state-of-the-art lab and office space joins our adjacent R&D facility at 1000 Sierra Point Parkway.
Bristol Myers Squibb is a global biopharmaceutical company whose vision is to transform patients’ lives through science. Nearly 500 employees across their Bay Area R&D sites in Brisbane and Redwood City are laying the foundation for innovative therapeutic approaches to cancer and other difficult-to-treat diseases.
Brisbane Mayor Madison Davis, San Mateo County Supervisor David Canepa and other elected officials and representatives from local, state and Congressional offices joined Bristol Myers Squibb leaders Robert Plenge, Executive Vice President, Chief Research Officer; Karin Shanahan, Executive Vice President, Global Product Development & Supply and Michael Pourdehnad, Senior Vice President, Early Clinical Development and Brisbane site head at the event to celebrate the impact of Bristol Myers Squibb on the local Bay Area life sciences, Brisbane and San Mateo County communities.
Other community partners present included San Mateo County Economic Development Association (SAMCEDA), Hypertrophic Cardiomyopathy Association, National Association for Advancement of Colored People (NAACP), Biocom California and California Life Sciences.
(Photo provided by Bristol Myers Squibb)